TMED1 Antibody (1009527) [Unconjugated]

HEK293 human embryonic kidney cell line transfected with (A) TMED-1 or (B) irrelevant protein, and eGFP were stained with Mouse Anti-Human TMED-1 Monoclonal Antibody (Catalog # MAB2243) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). Quadrant markers were set based Mouse IgG1 Isotype Control Antibody staining (Catalog # MAB002, data not shown). View our protocol for Staining Membrane-associated Proteins.

TMED1 was detected in immersion fixed A549 human lung carcinoma cell line using Mouse Anti-Human TMED1 Monoclonal Antibody (Catalog # MAB2243) at 8 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

• Reactivity: Hu
• Applications: Flow, CyTOF-ready, ICC/IF
• Clone: 1009527
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

TMED1 Antibody (1009527) [Unconjugated] Summary

• Immunogen: Human embryonic kidney cell, HEK293 derived human TMED1
  Met1-Asn194
  Accession # Q13445
• Specificity: Detects human TMED1 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells
  • Immunocytochemistry 8-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TMED1 Antibody (1009527) [Unconjugated]

• IL1RL1-Binding Protein
• Il1rl1l
• IL1RL1LG
• IL-1RL1LG
• IL1RL1LGIL1RL1-binding protein
• Interleukin 1 Receptor-Like 1 Ligand
• Interleukin-1 receptor-like 1 ligand
• Ly84l
• MGC1270
• P24g1
• P24gamma1
• Putative T1/ST2 receptor-binding protein
• ST2L
• T1/ST2 receptor binding protein
• TMED1
• Tp24
• transmembrane emp24 domain containing 1
• transmembrane emp24 domain-containing protein 1
• transmembrane emp24 protein transport domain containing 1

Background

TMED1 (Transmembrane Emp24 domain-containing protein 1) is a member of the TMED family of proteins (gene name TMED1). The TMED family of proteins are localized to membranes of the early secretory pathway, including the endoplasmic reticulum and Golgi, and function in vesicular protein trafficking (1, 2). TMED1 is a 59 kDa monomer and has been reported to exist as homodimer (3). TMED1 is composed of a 23 amino acid (aa) signal sequence, a 171 aa extra cellular domain, a 21 aa transmembrane domain, and a 12 aa cytoplasmic domain. The extracellular domain contains an 83 aa GOLD (Golgi Dynamics) domain, and COPI and COPII binding motifs are found in the cytoplasmic domain (1-3, 5). Human TMED1 shares 97% sequence identity with mouse, bovine, and rat homologs within the 171 aa extracellular domain. The beta -strand-rich GOLD domain has been specifically identified to be involved in intracellular protein trafficking (1, 4, 5). TMED1 is important in regulating innate immune signaling through its interaction with ST2L. Specifically, the GOLD domain in TMED1 interacts with the TIR domain of ST2L, a receptor for IL‑33 (1). This interaction promotes ST2L association with IL-33, allowing downstream signaling cascade activating MAP kinases, p38, and JNK (1, 6). Studies have shown knockdown of TMED-1 in HUVECs impairs the IL-33 induced response resulting in reduction of IL-6 and IL-8 productions (1).

1. Connolly, D. et al. (2013) J Biol Chem. 288:5616.
2. Gour, N. and Lajoie, S. (2018) Curr Allergy Ashma Rep. 16:65.
3. Jenne, N. (2002) J Biol Chem. 277:46504.
4. Anantharaman, V. and Aravind, L. (2002) Genome Biol. 3:research0023
5. Gomez-Navarro, N. and Miller, E. (2016) J Cell Biol. 215:769.
6. Hardman, C. and Ogg, G. (2016). Curr Opin Immunol. 42:16.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q13445()